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MeBACKGROUND ASCERT (American College of Cardiology Foundation and the Society of Thoracic Surgeons Collabo-
ration on the Comparative Effectiveness of Revascularization Strategies) was a large observational study designed to
compare the long-term effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention
(PCI) to treat coronary artery disease (CAD) over 4 to 5 years.
OBJECTIVES This study examined the cost-effectiveness of CABG versus PCI for stable ischemic heart disease.
METHODS The Society of Thoracic Surgeons and American College of Cardiology Foundation databases were linked to
the Centers for Medicare and Medicaid Services claims data. Costs for the index and observation period (2004 to 2008)
hospitalizations were assessed by diagnosis-related group Medicare reimbursement rates; costs beyond the observation
period were estimated from average Medicare participant per capita expenditure. Effectiveness was measured via
mortality and life-expectancy data. Cost and effectiveness comparisons were adjusted using propensity score matching
with the incremental cost-effectiveness ratio expressed as cost per quality-adjusted life-year gained.
RESULTS CABG patients (n ¼ 86,244) and PCI patients (n ¼ 103,549) were at least 65 years old with 2- or 3-vessel
coronary artery disease. Adjusted costs were higher for CABG for the index hospitalization, study period, and lifetime
by $10,670, $8,145, and $11,575, respectively. Patients undergoing CABG gained an adjusted average of 0.2525 and
0.3801 life-years relative to PCI over the observation period and lifetime, respectively. The life-time incremental
cost-effectiveness ratio of CABG compared to PCI was $30,454/QALY gained.
CONCLUSIONS Over a period of 4 years or longer, patients undergoing CABG had better outcomes but at higher costs
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2W hile death rates attributable tocoronary artery disease (CAD)have declined in recent years,
CAD remains (as it has for decades) the lead-
ing cause of death and disability in the
United States and the Western world (1).
Whereas randomized controlled trials
continue as the gold standard for comparing
therapeutic choices, the available data may
not be sufﬁcient to support many therapeu-
tic decisions. Additionally, the cost and
time constraints of developing randomized
controlled trials that cover all variables in
all populations render their ubiquitous use
impossible. Thus, in the ﬁeld of comparative
effectiveness research, nonrandomized data
must often be considered.SEE PAGE 12Comparisons from registry databases,
though subject to treatment selection bias,
can supplement randomized trials based
on speciﬁc advantages, such as greater
numbers, greater generalizability, and morecontemporary data that can be regularly updated.
Because of their size, representativeness, and reﬂec-
tion of real-world practice, observational databases
are becoming major contributors to comparative
effectiveness research (2,3).
In the area of cardiovascular disease, 2 prominent
registries, the American College of Cardiology
Foundation (ACCF) NCDR (National Cardiovascular
Data Registry) and the Society of Thoracic Surgeons
(STS) ACSD (Adult Cardiac Surgery Database), have
for several years individually supplied data for
several comparative effectiveness research out-
comes studies (4–9). The National Heart, Lung, and
Blood Institute of the National Institutes of Health
awarded a grant to the ACCF in partnership with
the STS to study the comparative effectiveness of
percutaneous coronary intervention (PCI) and coro-
nary artery bypass graft (CABG) surgery for treating
stable ischemic heart disease.
The resulting study, known as the ASCERT (Amer-
ican College of Cardiology Foundation–The Society of
Thoracic Surgeons Collaboration on the Comparative. Dr. Garratt consults for The Medicines Company and Boston S
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pared long-term outcomes of PCI and CABG using
these professional society databases as well as the
Centers for Medicare and Medicaid Services 100%
denominator ﬁle data (10). To further examine the
comparative efﬁcacy of CABG and PCI, we studied the
relative costs and cost-effectiveness of revasculariza-
tion strategies using ASCERT data.
METHODS
STUDY SUMMARY. A complete description of the
ASCERT study design and methods has been pub-
lished previously (11). Brieﬂy, ASCERT was a large
observational study designed to compare the long-
term effectiveness of CABG and PCI to treat CAD
over 4 to 5 years. The outcomes used to compare PCI
and CABG were death rates, need for additional or
repeat procedures, rehospitalization, and presenta-
tion of new cardiac disease conditions, such as stroke
or myocardial infarction (MI).
Patients were enrolled in ASCERT based on their
ﬁrst eligible revascularization record (index revascu-
larization). Data from 644 sites were available for
1,943,653 patients who underwent nonemergent
isolated CABG or PCI between 2004 and 2007. The
Centers for Medicare and Medicaid Services database
was linked to the NCDR CathPCI and ACSD registries,
yielding an analytic population of 189,793 patients,
including 86,244 CABG and 103,549 PCI patients
(Online Figure 1) (11).
ECONOMIC ANALYSIS PLAN AND ASSESSMENT OF
COST. The source for determining costs was patient-
level resource use from the ASCERT study. Direct
medical care costs associated with index hospitaliza-
tions were derived from resource use captured in
the ACCF and STS databases; subsequent hospitali-
zations and subsequent outpatient procedures were
obtained from the Centers for Medicare and Medicaid
Services dataset. The index and subsequent hospi-
talizations were assigned a diagnosis-related group
(DRG) in accordance with U.S. Medicare diagnostic
standards. Costs for each DRG were estimated using
average Medicare reimbursement rates obtained from
the Medicare Part A data ﬁle. Physician costs were
estimated by current procedural terminology codingcientiﬁc Corporation; and receives research support
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3of procedures and assigned a cost based on the
Medicare fee schedule.
Lifetime costs beyond the observation period and
costs not included in the hospitalization were esti-
mated from average Medicare participant per capita
expenditure, stratiﬁed by age group. Average Medi-
care participant per capita expenditure was $5,276 in
2004, the base year and the latest date with avail-
able data by age. The average costs for patients ages
65 to 74 years, 75 to 84 years, and 85 years or more
were $10,778, $16,389, and $25,691, respectively (12).
Costs (also for life-years and quality-adjusted life-
years [QALY]) beyond the ﬁrst year of follow-up
were discounted 3% annually (13). Drug-eluting
stent (DES) cost was reduced by 70%, since the DES
cost was substantially reduced over the study period
time.
LIFE-EXPECTANCY ESTIMATION. If death occurred
during the follow-up period, life-years lost were ob-
tained by subtracting the survival times recorded in
the ASCERT database from estimated age- and sex-
speciﬁc life-expectancy estimates for patients (14).
We assumed that the relationship between observed
age- and sex-speciﬁc mortality rates calculated fromTABLE 1 Baseline Characteristics
Unadjusted
CABG
(n ¼ 86,244)
PCI
(n ¼ 103,549) p Value
Age, yrs 73  6 75  7 <0.0001
Male 69 58 <0.0001
History of heart failure 12 10 <0.0001
History of MI 25 25 0.0001
Diabetes 39 34 <0.0001
Insulin-RDM 10.2 9.8 0.0069
Hypertension 85 83 <0.0001
Renal failure 6.1 6.2 0.57
Chronic lung disease 21 19 <0.0001
Cerebrovascular disease 18 16 <0.0001
Peripheral artery disease 18 15 <0.0001
BMI, kg/m2 29  6 29  6 0.78
Former smoker 44 43 <0.0001
Current smoker 13 12 <0.0001
No angina 22 31 <0.0001
Stable angina 50 23 <0.0001
Unstable angina 28 47 <0.0001
Ejection fraction 53  13 55  13 <0.0001
Vessels diseased
2 20 68 <0.0001
3 80 32
Status urgent 35 36 <0.0001
Values are mean  SD or %.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; MI ¼ myocardial infarthe ASCERT patients and expected corresponding
mortality rates from U.S. Life Table would continue to
apply to the still-alive ASCERT patients in the future
(Online Appendix, Supplement: Life Expectancy
Estimation).
For patients with nonfatal MI and/or stroke events
during follow-up, additional age- and sex-speciﬁc
life-expectancy adjustments were made using Fra-
mingham Heart Study (13,14) risk estimations and
added to the results obtained in the previous step
(Online Table 1) (15–17).
The EuroSCORE II (European System for Cardiac
Operative Risk Evaluation II) (18) risk was calculated
to adjust the estimation of life-years lost for each
treatment group and reﬂect the uncertainties in long-
term mortality. The EuroSCORE II for each patient
was estimated based on patient factors, cardiac fac-
tors, and operation factors.
QUALITY-ADJUSTED LIFE-YEARS. Life-years may be
limited for comparison across studies and disciplines
because a person in perfect health will derive more
value for a life-year saved than a patient in impaired
health will. This is addressed by calculating QALY. In
ASCERT, QALY were calculated by multiplyingInverse Probability Weighted Adjusted Matched Data
CABG
(n ¼ 86,244)
PCI
(n ¼ 103,549) p Value
CABG
(n ¼ 43,084)
PCI
(n ¼ 43,084) p Value
74  9 74  8 0.49 74  6 74  6 0.62
62 63 0.17 64 64 0.69
11 11 0.07 11 11 0.31
25 25 0.51 24 24 0.89
36 36 0.97 37 37 0.63
9.7 9.9 0.35 10.1 10.0 0.66
84 84 0.58 84 84 0.37
6.1 6.1 0.80 6.2 6.2 0.84
19 20 0.50 20 20 0.99
17 17 0.86 17 17 0.93
16 16 0.97 16 17 0.45
29  9 29  8 0.97 29  6 29  6 0.58
43 43 0.45 43 43 0.37
12 12 0.74 12 12 0.39
26 27 0.23 28 28 0.94
35 35 0.46 34 34 0.65
39 38 0.066 38 38 0.71
54 54 0.58 54  12 54  13 0.43
47 46 0.043 37 37 0.88
53 54 63 63
36 35 0.051 36 36 0.43
ction; PCI ¼ percutaneous coronary intervention; RDM ¼ requiring diabetes mellitus.
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4survival by utility, a measure of health status scaled
from 0 (death) to 1 (perfect health).
QALY were estimated from published data on
utilities and estimates of survival, because utility
measures were not available from the ACCF or STS
databases. Utility was determined on the basis of
whether a patient experienced nonfatal cardiovascularCENTRAL ILLUSTRATION Tables Demonstrating Effective
and Lifetime
Costs Over Time Period Studied a
ITEM
Index Hospitalization
From 2004 to 2008
Lifetime
Lifetime (adjusted by PSBB)
From 2004 to 2008
(adjusted by PSBB)
Index Hospitalization 
(adjusted by PSBB)
Effectiveness:  Life Years
ITEM
Life Years Lost Due to Death 
(3% discount)
From 2004 to 2008
Lifetime
Estimated Life Years Lost 
(3% discount)
Estimated Life Years Lost 
(adjusted by PSBB)
Life Years Lost Due to Death 
(3% discount, adjusted by PSBB)
Quality Adjusted Life Years Lost 
(3% discount, adjusted by PSBB)
$24,422
$64,976
$196,256
$184,933
$63,785
$24,290
CABG
(N=86,244)
1.1106
CABG
(N=86,244)
0.9647
1.4132
1.2248
0.9868
(
(
Zhang, Z. et al. J Am Coll Cardiol. 2015; 65(1):1–11.
The ﬁrst table evaluates the effectiveness by reviewing life-years lost f
graft (CABG) compared with percutaneous coronary intervention (PCI) un
second table presents the costs indexes for hospitalization, from 2004
PSBB adjusted. CI ¼ conﬁdence interval.events or a stroke. The utilities were taken from the
Cost-Effectiveness Analysis Registry and age-speciﬁc
utility estimates were applied from population-based
studies (19).
ESTIMATION OF COST-EFFECTIVENESS. The cost-
effectiveness of CABG was expressed as the incre-
mental cost-effectiveness ratio (ICER), deﬁned as theness and Cost of Index, Over the Study Period,
nd Lifetime by Treatment Group 
95% CI OF 
 Lost and Years Gained 
95% CI OF 
$13,373
$56,652
$187,532
$173,358
$55,640
$13,620
N=103,549)
PCI
1.2285
N=103,549)
PCI
1.2172
1.6023
1.5264
1.3669
$11,049
$8,323
$8,724
$11,575
$8,145
$10,670
(CABG-PCI)
0.1178
(CABG-PCI)
0.2525
0.1891
0.3016
0.3801
10,175 - 12,051
7,446 - 9,145
7,121 - 9,127
10,046 - 12,318
7,125 - 9,013
9,624 - 11,352
0.0897 - 0.1459
0.2254 - 0.2772
0.1313 - 0.1949
0.2660 - 0.3287
0.3516 - 0.4074
or each procedure and life-years gained with coronary artery bypass
adjusted and propensity score bin bootstrapping (PSBB) adjusted. The
through 2008, and for lifetime by treatment group unadjusted and
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5additional cost of CABG divided by the life-years
gained and QALY gained compared to PCI. Mean
costs for each strategy were calculated as well as the
mean difference. Direct medical care costs associated
with index hospitalizations, subsequent hospitaliza-
tions, and total costs were considered in this analysis.
Because the distribution of the differences for cost
and effectiveness is typically skewed, the statistics of
the difference were estimated by bootstrap analysis
(17).
To reduce treatment selection bias in this obser-
vational study, propensity score bin bootstrapping
methods (PSBB) were used to estimate the 95% con-
ﬁdence interval (CI) for the mean differences of cost
and effectiveness between the 2 strategies (10,000
replicates) (20) (Online Appendix: Supplements:
Propensity Model and Included Variables and PSBB
Approach). Furthermore, to ensure transparency and
comparability of the CABG and PCI population, 1-to-1
matching without replacement was conducted to
generate an analytic population that was restricted to
CABG and PCI patients matching in 3 or more deci-
mals of propensity scores. Baseline characteristics
were assessed to ensure the balance of patients for
the matched population.
An observational study with a large sample size
offers an important source for revealing heteroge-
neity of different patient characteristics, providing
sufﬁcient power to conduct subgroup cost-
effectiveness analysis deﬁned by age ($75 years
and <75 years), diabetes status, anginal status (none,
stable, or unstable), 2-vessel, or 3- or more vessel
disease, and heart failure status. Cost-effectiveness
was assessed in these subgroups using the same
methods as in the overall matched analytic
population.
Traditional 1-way sensitivity analyses included
varying life-years gained for the CABG versus PCI
group by 10% to 40%. Meanwhile, the impact of un-
measured confounding factors on cost-effectiveness
has been a crucial uncertainty and was assessed
(21). Probabilistic sensitivity analyses evaluated theTABLE 2 Cost-Effectiveness Analysis: PSBB Adjusted
D CABG-PCI
Life-Years or QAL
Gained With CABG
Life-years from 2004 through 2008 $8,323 0.1178
Life-years from 2004 through 2008:
3% discount and PSBB adjusted
$8,088 0.3088
Lifetime: 3% discount and PSBB adjusted $11,575 0.3016
Quality-adjusted lifetime:
3% and PSBB adjusted
$11,575 0.3801
ICER ¼ incremental cost-effectiveness ratio; LYG ¼ life-years gained; PSBB ¼ propensitimpact of simultaneous changes of all the variables
involved in the cost and life-years gained. Monte
Carlo simulation was performed to derive the differ-
ences in QALY and mean cost between the 2 treat-
ment groups (22).
RESULTS
CLINICAL DATA SUMMARY. The study included a
total of 189,793 patients, of whom 86,244 patients
underwent CABG and 103,549 patients underwent
PCI (Table 1). There were signiﬁcant differences
between these groups in both demographic and
clinical characteristics prior to adjustment. A
matched analytic population (n ¼ 43,084 for each
treatment group) was obtained via 1-to-1 matching in
3 or more decimals of propensity scores. Table 1
shows the comparison of baseline characteristics by
treatment group with unadjusted data, adjusted by
inverse probability weighted (IPW), and matched
analytic population. Age, sex, and most clinical
covariates were well balanced between the CABG and
PCI groups for both IPW-adjusted data and matched
analytic data. Note that the number of vessels
diseased and urgent status were not balanced by the
IPW-adjusted population, but were similar in the
matched analytic population.
EFFECTIVENESS: LIFE-YEARS LOST, LIFE-YEARS
GAINED, AND QALY LOST. The Central Illustration
shows effectiveness: life-years lost in the CABG and
PCI groups; life-years gained with CABG compared
with those gained with PCI plus PSBB and quality-
adjusted survival results over the follow-up period
from 2004 through 2008; and estimated life-time
results. Over the follow-up period, before adjust-
ment, there was a signiﬁcant difference in life-years
lost between the groups (1.1106 and 1.2283 life-
years lost for the CABG and PCI groups, respec-
tively), resulting in 0.1178 life-years gained for CABG
versus for PCI; the PSBB-adjusted years lost were
0.9647 and 1.2172 in the CABG and PCI groups,Y
ICER
% CABG
Dominated
% CABG
Dominant % <$30,000/LYG % <$50,000/LYG % <$100,000/LYG
$70,647 0 0 0 0 99.0
$26,192 0 0 70 97.0 100.0
$38,379 0 0 3.0 91.0 99.0
$30,454 0 0 47.0 98.0 100.0
y score bin bootstrapping; QALY ¼ quality-adjusted life-year(s); other abbreviations as in Table 1.
TABLE 3 Cost-Effectiveness Analysis: Matched Analytic Population
D CABG-PCI
Life-Years or QALY
Gained With CABG ICER
% CABG
Dominated
% CABG
Dominant % <$30,000/LYG % <$50,000/LYG % <$100,000/LYG
Life-years from 2004
through 2008
$8,079 0.2674 $30,217 0 0 45.0 100.0 100.0
Lifetime: 3% discount $12,157 0.3172 $38,330 0 0 0 100.0 100.0
Quality-adjusted lifetime:
3% discount
$12,157 0.3947 $30,803 0 0 21.0 100.0 100.0
Abbreviations as in Tables 1 and 2.
TABLE 4
Diabetes
No diabet
Age >75 y
Age #75 y
White
Nonwhite
Male
Female
No angina
Stable ang
Unstable a
2-vessel d
$3-vessel
HF
No HF
HF ¼ heart
Zhang et al. J A C C V O L . 6 5 , N O . 1 , 2 0 1 5
Cost-Effectiveness of Revascularization Strategies J A N U A R Y 6 / 1 3 , 2 0 1 5 : 1 – 1 1
6respectively, resulting in 0.2525 life-years gained
with CABG versus PCI.
For lifetime, unadjusted life-years lost was 1.4132
and 1.6023 in the CABG and PCI groups, respectively;
the quality- and PSBB-adjusted years lost were
0.9868 and 1.3669 in the CABG and PCI groups,
respectively, resulting in 0.3801 PSBB-adjusted QALY
gained for CABG versus for PCI. Similar results were
shown for the matched analytic population (Online
Table 2).
COSTS: 2004 THROUGH 2008 AND LIFETIME. As
seen in the Central Illustration, index hospitalization
cost remained signiﬁcantly higher for the CABG group
than in the PCI group, by $11,049 before and $10,670
after adjustment. The adjusted average total cost over
the follow-up period was higher in the CABG group by
$8,145 ($63,783 in CABG vs. $55,640 in PCI). The dif-
ference in cost during the follow-up period (2004
through 2008) was mainly due to the difference in
index hospitalization cost. This trend remained for
estimated lifetime cost.Cost-Effectiveness Analysis for Matched Analytic Population Subgroup
D CABG-PCI
Life-Years or QALY
Gained With CABG ICER
% CABG
Dominated
%
D
$14,069 0.5525 $25,467 0
es $11,075 0.3051 $36,298 0
rs $12,407 0.3863 $32,118 0
rs $11,806 0.4046 $29,182 0
$12,021 0.3999 $30,060 0
$13,377 0.3511 $38,102 0
$11,496 0.3922 $29,309 0
$13,432 0.3987 $33,693 0
$14,914 0.5842 $25,527 0
ina $9,600 0.2262 $42,443 0
ngina $12,439 0.4066 $30,484 0
isease $10,943 0.2589 $42,269 0
disease $12,883 0.4758 $27,080 0
$20,213 0.8216 $24,602 0
$11,090 0.3376 $32,848 0
failure; other abbreviations as in Tables 1 and 2.The unadjusted lifetime cost in the CABG group
was $8,742 higher than in the PCI group ($196,256 vs.
$187,532). The PSBB-adjusted lifetime cost was
$184,933 in the CABG group and $173,358 in the PCI
group, still signiﬁcantly higher for CABG by $11,575.
A similar trend was seen in the matched analytic
population (Online Table 3).
COST-EFFECTIVENESS ANALYSIS FOR FOLLOW-UP
AND LIFETIME. Table 2 (PSBB-adjusted) and Table 3
(matched analytic population) show the cost-
effectiveness analysis for the follow-up period and
lifetime. For lifetime, the PSBB-adjusted ICER of
CABG compared to PCI was $38,379 per life-years
gained (LYG), with 3.0% and 91.0% of observations
below $30,000 and $50,000 per LYG, respectively,
and 99.0% below $100,000 per LYG; the further
quality-adjusted ICER of CABG compared to PCI was
$30,454 QALY gained, with 47.0% and 98.0% of ob-
servations below $30,000 and $50,000 per QALY
gained, respectively, and 100% below $100,000 per
QALY gained (Figure 1A).s
CABG
ominant % <$30,000/LYG % <$50,000/LYG % <$100,000/LYG
0 100.0 100.0 100.0
0 0 100.0 100.0
0 1.0 100.0 100.0
0 70.0 100.0 100.0
0 46.0 100.0 100.0
0 0 95.0 100.0
0 72.0 100.0 100.0
0 0 100.0 100.0
0 99.0 100.0 100.0
0 0 94.0 100.0
0 37.0 100.0 100.0
0 0 95.0 100.0
0 99.0 100.0 100.0
0 100.0 100.0 100.0
0 0 100.0 100.0
FIGURE 1 Scatterplot of Joint Distribution of Cost and Effectiveness Differences
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Scatterplot of the joint distribution of cost and effectiveness differences in the cost-effectiveness plane for the lifetime analysis. Results via
(A) PSBB adjusted method and (B) the matched analytic population. CABG ¼ coronary artery bypass graft; PCI ¼ percutaneous coronary
intervention; PBSS ¼ propensity score bin bootstrapping; QALY ¼ quality-adjusted life-year(s).
FIGURE 2 Cost-Effectiveness Acceptability Curve
CEA Curve for
Matched Data 
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CEA Curve by PSBB Adjusted
The cost-effectiveness acceptability (CEA) curve for CABG versus
PCI demonstrates that for the lifetime analysis, the matched
analytic population curve rises more steeply than that for
PSBB adjusted initially, but the 2 converge over a lifetime. The
y-axis corresponds to the probability of observations below
corresponding incremental cost-effectiveness (CE) ratio.
Abbreviations as in Figure 1.
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7Table 3 shows that the cost-effectiveness results
for matched analytic populations were similar to
those using the PSBB-adjusted method. For lifetime,
the quality-adjusted ICER of CABG compared to PCI
was $30,803 QALY gained, with 21.0% and 100.0% of
observations below $30,000 and $50,000 per QALY
gained, respectively (Figure 1B). Using a common
threshold such as $50,000 per QALY gained, results
from both the PSBB-adjusted and matched analytic
population approaches illustrated that CABG pro-
vided moderate to high probability of better clinical
beneﬁt, which means CABG will often be a cost-
effective strategy (Figure 2).
SUBGROUP ANALYSIS. Subgroup lifetime cost-
effectiveness analyses were performed for the
matched analytic population. Similar results were
obtained for all patients via PSBB (not shown).
Results in Table 4 demonstrate differences in terms
of patient features (Online Appendix: Supplement:
Subgroup Analysis). For instance, ICER were
$42,443 per QALY and $42,269 per QALY for stable
angina and 2-vessel disease patients, respectively,
and both with 0% of observation below $30,000 per
QALY.
SENSITIVITY ANALYSIS. There is uncertainty regarding
years of life lost due to early death and the impact of
nonfatal MI or stroke on subsequent life expectancy.
FIGURE 3 Sensitivity Analyses
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8Thus, for the matched analytic population over a
lifetime, if the quality-adjusted beneﬁt of CABG
relative to PCI decreased by 10%, 20%, 30%, and 40%,
the ICER would increase from $30,803 to $34,400,
$39,330, $45,660, and $54,100 per QALY gained,
respectively. In contrast, if the estimated and
adjusted QALY gained with CABG relative to PCI
increased by 10%, 20%, 30%, and 40%, the ICERf Unmeasured Confounder Factors on ICER
10 20 30 40 50
Prevalence of confounder in PCI Group (%)
Prevalence of Confounder
in CABG Group
5%
10%
20%
30%
40%
60 70 80 90 100
asured confounder factor. Abbreviations as in Figures 1 and 3.would decrease from $30,803 to $27,240, $24,550,
$22,280, and $20,930 per QALY gained, respectively
(Figure 3).
Figure 4 represents the impact of a single unmea-
sured confounder on the ICER as a combination of
cost and effectiveness, to account for the advantage
of CABG over PCI detected in the study. From the
adjusted survival analysis in ASCERT, if an unmea-
sured risk factor was present in 10% of the patients in
the CABG group and in 20%, 35%, or 50% of the PCI
patients, then the hazard ratio that would be
required for the observed decreased risk with CABG
would be 4.25, 2.09, and 1.65, respectively (11). The
unmeasured confounder could also have affected the
observed cost difference, ranging from a decrease of
20% to an increase of 10% (23). If the prevalence due
to the confounder in PCI was 50%, the ICER of CABG
versus PCI would change from $24,000, to $28,000, to
$33,000, to $38,000, and to $41,000 per QALY gained
for the prevalence of the confounder in CABG with
5%, 10%, 20%, 30%, 40%, respectively.
To account for uncertainties regarding years of
life lost due to early death, the impact of nonfatal
MI or stroke on subsequent life expectancy and the
estimation of cost due to differences in the use of
resources, a probabilistic sensitivity analysis was
conducted to assess the robustness of the estimates
for matched analytic population. The results of
EuroSCORE II are shown in the Online Appendix:
Supplement: EuroSCORE II. The distributional as-
sumptions of the cost data were based on the actual
data in this study and their ranges come from rele-
vant literature, with probabilities of effectiveness
(Online Table 4) derived from other cardiovascular
studies and resources such as the American Heart
Association Heart Disease and Stroke Statistical
Update (1). Figure 5A presents the contour plot of
simulated distribution of mean differences in cost
and effectiveness using matched analytic population
and quality adjustment, based on the probabilistic
sensitivity analysis over a lifetime. The ellipses
indicate 50%, 95%, and 99% CI of the simulated
lifetime ICER. It reveals that the IPW-adjusted life-
time QALY gained could range from 0.27 to about
0.65 years for the CABG group compared with those
for the PCI group; on the other hand, the cost for
the CABG group would always be signiﬁcantly
larger, varying from $5,500 to $17,800, indicating
a better clinical beneﬁt for CABG but at increased
cost.
The cost-effectiveness acceptability curve (Figure
5B) illustrates that the variation the ICER considered
in this sensitivity analysis was greater than noted
purely by the play of chance in the base case;
FIGURE 5 Probabilistic Sensitivity Analyses
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9speciﬁcally, compared with 21.0% of observations
below $30,000 per QALY gained, and 100% below
$50,000 per QALY gained for the base case, there was
a 33% probability of CABG being cost-effective at
the $30,000 threshold and 100% at the $50,000
threshold. The probability of CABG being dominated
by PCI was <1%. Sensitivity trends were similar for
all patients adjusted using the PSBB approach.
DISCUSSION
We performed a cost-effectiveness analysis of
ASCERT; the main clinical results showed that there
was a long-term survival advantage in older patients
with nonemergent multivessel CAD who were
selected to have CABG rather than PCI. The present
economic analysis shows CABG is more expensive
than PCI is, almost entirely due to the initial proce-
dural costs (Central Illustration). It is reasonable to
conclude that, after the study period, resource use
and costs would largely track in parallel. A long-term
survival advantage among patients in the CABG
group was converted into QALY gained (Central
Illustration), but the point estimates for the ICER
for potential CABG beneﬁt were below common
benchmarks (Tables 2 and 3).
To address selection bias in this large obser-
vational study, analyses were conducted through
both PSBB and a matched analytic population.
PSBB captured the information from all patientswith balance achieved for measured confounders
via propensity score adjustment. The 1-to-1 matched
analytic population indeed had better risk factor
balance between the CABG and PCI groups,
but approximately one-third of the patients were
excluded from the analysis. Nonetheless, the
similarity of results from PSBB method and
matched analytic population enhances the results’
reliability.
Although the greatest uncertainty is in the differ-
ential life expectancy, these results are robust to
variations in relative gain in life expectancy with
CABG, both before and after PSBB adjustment, and for
the matched analytic population.
It is natural to evaluate our ﬁndings in the context
of results from other health economic studies. In
2006, on the basis of a Department of Veterans Affairs
Cooperative Study randomizing high-risk patients
with medically refractory myocardial ischemia, a cost-
effectiveness assessment of CABG (n ¼ 227) versus PCI
(n ¼ 218) for high-risk patients showed that PCI was
less costly and at least as effective for the urgent
revascularization of medically refractory, high-risk
patients over 5 years. After 5 years, average total
costs were $81,790 for PCI versus $100,522 for CABG
patients, a difference of $18,732 (95% CI: $9,873 to
$27,831), whereas survival at 5 years was 0.75 for PCI
patients versus 0.70 for CABG patients (p ¼ 0.21)
(23). The FREEDOM (Future Revascularization Evalu-
ation in Patients with Diabetes Mellitus: Optimal
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10Management of Multivessel Disease) trial was a 5-year
study between 2005 and 2010 of 1,800 patients with
diabetes and multivessel CAD who were randomly
assigned to CABG or PCI with DES at 140 centers
throughout the world. Investigators reported that
CABG was associated with 0.66 QALY gained and
higher costs of approximately $5,400 per patient;
lifetime cost-effectiveness of CABG was therefore
$8,132 per QALY gained, which is signiﬁcantly lower
than the commonly used benchmark of $50,000 per
QALY gained for considering a treatment to be cost-
effective (24). The SYNTAX (Synergy Between PCI
With Taxus and Cardiac Surgery) trial randomized
1,800 patients with left-main or 3-vessel CAD to CABG
(n ¼ 897) or DES-PCI (n ¼ 903) between 2005 and 2007.
Over a lifetime horizon, CABG remained more costly
than DES-PCI with a favorable ICER of $16,537/QALY
gained (25). Our ASCERT results demonstrated a
similar trend, but exhibited some discrepancy in ICER
values. The discrepancy may be due to the change of
survival rate of CABG versus PCI, such as no difference
in survival between groups at 1 year, but signiﬁcant
better beneﬁt in survival in CABG group at 4 years.
The differences over a lifetime may reﬂect diverse
assumptions in estimating life expectancy in both
arms of the studies.
Using professional society databases, we demon-
strated the distinct advantages of linking clinical
and administrative databases. Clinical databases
are well suited to risk adjustment and the identiﬁ-
cation of clinically important subgroups, but lack
long-term outcome information. Administrative
datasets have limited capacity for clinical con-
siderations, but they do provide long-term infor-
mation on outcomes as well as cost of care.
Linking the clinical data with administrative data
capitalizes on the distinct advantages of each data-
set to create a powerful analytic tool for obser-
vational studies.
STUDY LIMITATIONS. ASCERT is a nonrandomized
observational study, and although PSBB/IPW adjust-
ment created CABG and PCI populations demon-
strating excellent balance, enabling a more valid
comparison, there remains a potential for unmea-
sured confounders to have inﬂuenced the estimation
of both clinical outcomes and cost. Although our cost-
effectiveness analysis sought a societal basis, costs
such as DRG-based values were estimated from a
payer perspective. It is also not generally possible to
account for all costs and for all utilization. Resource
use beyond the trial period is based on a model, not
on direct measurement. For instance, costs beyondthe period of observation were estimated from
average Medicare participant expenditures stratiﬁed
by age.
For patients still alive at the end of the follow-up
period, we applied a Monte Carlo simulation
method to estimate the life expectancy on the basis
of the observed mortality rate and the U.S. Life
Tables (2009) and converted to life-year lost for
each procedure. Our methods are an estimate both
of patients’ health status (utility) and projected
survival. We used Framingham data, an external
database, to estimate nonfatal events related to life
expectancy. The Framingham database, however,
may not reﬂect multiple advances in medical care,
speciﬁcally in cardiovascular medicine, that have
occurred since that database was created. Projection
of life expectancy for disease-speciﬁc patients and
cost beyond the observational period must be based
on models developed from the literature. Evaluation
of utility, used to quality adjust survival, is also
problematic, with utility estimates not directly from
the dataset. Although propensity matching balanced
the patients, some important covariates that should
have been included in the propensity model could
have been missed. It is likely that the accurate
estimation of difference in life expectancy was
limited. Despite these limitations, the results of our
sensitivity analyses were robust, suggesting that the
results are unlikely to be severely affected as long
as there is a survival beneﬁt of CABG in keeping
with the ASCERT results.
Finally, there is no scientiﬁc basis for a threshold to
establish whether a therapy is cost-effective. The
commonly used threshold of $50,000 is an approxi-
mation of societal “willingness to pay.”
CONCLUSIONS
This study shows that over a period of 4 years or
longer, CABG is associated with better outcomes but
at higher cost than PCI among older patients with 2-
or 3-vessel CAD. Under the assumption that our
analysis has fully accounted for both measured
and unmeasured confounding, in patients with
stable ischemic heart disease, CABG will often be
considered cost-effective at thresholds of $30,000
or $50,000/QALY.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Compar-
ison of PCI and CABG surgery allow assessment of the
effectiveness of the 2 procedures for treatment of pa-
tients with multivessel disease. Observational and clinical
trial data have demonstrated a survival advantage asso-
ciated with CABG, but surgery is more expensive, due
almost entirely to the initial costs associated with the
operation.
TRANSLATIONAL OUTLOOK: Analyses that link clin-
ical and administrative databases can be applied to other
aspects of patient management to enhance insights from
observational studies and clinical registries about the
relative value of various options and inform shared deci-
sion making between patients and providers.
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